University of Rochester
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Rochester sits in the top decile of US sponsors by registered trial count (#53 of 15,742 sponsors by registered trial count).
University of Rochester: 636 sponsored US clinical trials, 94 recruiting.
University of Rochester sponsors 636 registered US clinical trials on ClinicalTrials.gov, 94 of them currently recruiting, and 448 completed. 54 of these trials are in Phase 3-4 (later-stage) and 147 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cancer, with 7 trials.
Top-decile sponsor footprint
University of Rochester ranks in the top decile of sponsors by registered trial count (#53 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
448 of 506 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
636 total, page 11 of 13
Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS
NCT00638196
Uroflow Measurements in Healthy Volunteers
NCT00714389
Triclosan Toothpaste and Third Molar Surgery
NCT01292343
Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy
NCT01091974
Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients
NCT01042938
Use of Teriparatide to Accelerate Fracture Healing
NCT00594906
Exercise for Prostate Cancer Patients
NCT00815672
Characteristics of Andersen-Tawil Syndrome
NCT00521794
Voiding Dysfunction in the Postoperative Period Following Placement of the TVT
NCT00713908
Measurement of the Radiation Dose Cuticles Using Electron Paramagnetic Resonance (EPR)
NCT00904189
Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma
NCT00547534
Influenza Vaccine in Premature Infants
NCT00455169
Recovery After Robotic Urogynecological Surgery: The Patient's Perspective
NCT00757432
A Pilot, Randomized Controlled Trial of Group Visits for Persons With Parkinson's Disease
NCT00528086
CoolCap Followup Study-Coordination of Participating Centers
NCT00581581
Women's Depression Treatment Study
NCT00843700
Activated Protein C in Acute Stroke Trial
NCT00533546
Building Healthy Children
NCT01888809
Hyper- and Hypokalemic Periodic Paralysis Study
NCT00494507
Screening and Interventions in an Acute Care Setting
NCT00545155
Study of the SafeSeal(TM) Hemostasis Patch Following Percutaneous Coronary Artery and Peripheral Vascular Interventions
NCT00481741
Exercise for Breast Cancer Patients (EXCAP)
NCT00851812
Trial of Patient Navigation-Activation
NCT00496678
Moxifloxacin vs. Polytrim for Conjunctivitis
NCT00581542
Teen Asthma Project
NCT01161225
Centocor Microarray Study of Patients
NCT00462072
Psychosocial Treatment for Women With Depression and Pain
NCT00895999
NET-PD LS-1 Creatine in Parkinson's Disease
NCT00449865
NICU Asthma Education and Secondhand Smoke Reduction Study
NCT00499915
Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis
NCT00414453
Assessing the Effectiveness of Concurrent Peer Review for Patients With Cardiovascular Disease and Diabetes
NCT00508014
Sedation in Patients at Risk for Upper Airway Collapse
NCT01045122
Vascular CT Assessment of Structural Autograft and Allograft Healing
NCT00594776
PROS Smokebusters: Adolescent Smoking Cessation in Pediatric Primary Care
NCT00135265
Assessment of Two Postoperative Techniques Used to Predict Voiding Efficiency After Gynecologic Surgery
NCT00392210
A Comparison of Manual vs. Spontaneous Removal of the Placenta at Cesarean Section
NCT00375986
School-based Asthma Therapy: Stage 2 Effectiveness Study
NCT01175369
Memantine for Spasticity in MS Patients
NCT00638027
Outcomes and Patient Satisfaction After Colpocleisis for Pelvic Organ Prolapse
NCT00714155
Transfusion Strategies in Pediatric Cardiothoracic Surgery
NCT00350220
Safety and Efficacy of DepoDur in Lumbar Spine Surgery Patients
NCT00335517
Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma
NCT00317798
Mindfulness to Improve Elders' Immune and Health Status
NCT01027780
Namenda to Prevent Post-Operative Delirium
NCT00303433
A Randomized Study of Polarity or Massage Therapy to Reduce Fatigue in Breast Cancer Patients During Radiation Therapy
NCT00288795
Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy
NCT00283816
Sleep Homeostasis in Primary Insomnia
NCT00256503
Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)
NCT00233519
Acupressure and Relaxation for Nausea Control
NCT00243269
A Multi-Center Trial of Botox for Severe Urge Urinary Incontinence
NCT00345332
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 66 |
| Phase 2 | 81 |
| Phase 3 | 20 |
| Phase 4 | 34 |
Therapeutic Areas
What is open in the University of Rochester pipeline
94 recruiting of 636 indexed (15% open); 448 completed (70%).
Phase mix: 54 late (III/IV) vs 147 early (I/II) (early-phase heavy).
Top condition: Cancer (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Rochester: open-pipeline peers nationwide
Peers matched on 636 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
University of Rochester sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 636 trials (± recruiting share)
- US Department of Veterans Affairs · 632 trials · 0% recruiting
- University of Southern California · 617 trials · 16% recruiting
- Baylor College of Medicine · 616 trials · 15% recruiting
- University of California, Davis · 657 trials · 19% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Loma Linda University · 15% recruiting · 237 trials
- Dompé Farmaceutici S.p.A · 15% recruiting · 27 trials
- Vanderbilt-Ingram Cancer Center · 15% recruiting · 189 trials
- Brown University · 15% recruiting · 231 trials
Related
What to do with this University of Rochester page
636 registered trials is a research-attention snapshot, not an endorsement of University of Rochester or any single study.
- 94 of University of Rochester's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cancer is the condition University of Rochester studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Rochester pipeline card: 636 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.